Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia

Leukemia

Volumn 12, Issue 10, 1998, Pages 1527-1533

  Woo, M H ^a   Hak, L J ^a   Storm, M C ^a   Evans, W E ^a,b   Sandlund, J T ^b,c   Rivera, G K ^b,c   Wang, B ^a   Pui, C H ^b,c   Relling, M V ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Acute lymphoblastic leukemia; Allergic reaction; Antibodies; Asparaginase

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DRUG ANTIBODY; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; REAGENT; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DEVICE; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0031681258     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401162     Document Type: Article

References (21)

1. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, Peterson RG, Handschumacher RE. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901.
2. Haskell CM, Canellos CP. L-asparaginase resistance in human leukemia - asparagine synthetase. Biochem Pharmacol 1969; 18: 2578-2580.
3. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786.
4. Evans WE, Tsiatis A, Rivera G, Murphy SB, Dahl GV, Denison M, Crom WR, Barker LF, Mauer AM. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49: 1378-1383.
5. Billet AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70: 201-206.
6. Yoshimoto T, Nishimura H, Saito Y, Sakurai K, Kamisaki Y, Wada H, Sako M, Tsujino G, Inada Y. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn J Cancer Res 1986; 77: 1264-1270.
7. Park YK, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. Anticancer Res 1981; 1: 373-376.
8. Dellinger CT, Miale TD. Comparison of anaphylactic reactions to asparaginase derived from Escherichia coli and from Erwinia cultures. Cancer 1976; 38: 1843-1846.
9. Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972; 30: 376-381.
10. Killander D, Dohlwitz A, Engstedt L, Franzen S, Gahrton G, Gullbring B, Holm G, Holmgrem A, Hoglund S, Killander A et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976; 37: 220-228.
11. Peterson RG, Handschumacher RE, Mitchell MS. Immunological responses to L-asparaginase. J Clin Invest 1971; 50: 1080-1090.
12. Oettgen HF, Stephenson PA, Schwartz MK, Leeper RD, Tallai L, Tan CC, Clarkson BD, Golbey RB, Krakoff IH, Karnofsky DA et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25: 253-278.
13. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
14. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986; 8: 99-104.
15. Land VJ, Sutow WW, Fernbach DJ, Lane DM, Williams TE. Toxicity of L-asparaginase in children with advanced leukemia. Cancer 1972; 30: 339-347.
16. Nesbit M, Chard R, Evans A, Karon M, Hammond GD. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1: 9-13.
17. Jacquillat C, Weil M, Bussel A, Loisel JP, Rouesse T, Larrieu MJ, Boiron M, Dreyfus B, Bernard J. Treatment of acute leukemia with L-asparaginase - preliminary results on 84 cases. Recent Res Cancer Res 1970; 33: 263-278.
18. Ahlke E, Nowak-Gottl U, Schulze-Westhoff P, Werber G, Borste H, Wurthwein G, Jurgens H, Boos J. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Haematol 1997; 96: 675-681.
19. Jaffe N, Traggis D, Das L, Moloney WC, Hann HW, Kim BS, Nair R. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971; 31: 942-949.
20. King OY, Wilbur JR, Mumford DM, Sutow WW. Therapy with Erwinia L-asparaginase in children with acute leukemia after anaphylaxis to E. coli L-asparaginase. Cancer 1974; 33: 611-614.
21. Gentili D, Conter V, Rizzari C, Tschuemperlin B, Zucchetti M, Orlandoni D, D'Incalci M, Masera G. L-asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol 1996; 7: 725-730.